Does ADALIMUMAB Cause Bladder transitional cell carcinoma? 96 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 96 reports of Bladder transitional cell carcinoma have been filed in association with ADALIMUMAB (YUSIMRY). This represents 0.0% of all adverse event reports for ADALIMUMAB.
96
Reports of Bladder transitional cell carcinoma with ADALIMUMAB
0.0%
of all ADALIMUMAB reports
0
Deaths
72
Hospitalizations
How Dangerous Is Bladder transitional cell carcinoma From ADALIMUMAB?
Of the 96 reports, 72 (75.0%) required hospitalization, and 3 (3.1%) were considered life-threatening.
Is Bladder transitional cell carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ADALIMUMAB. However, 96 reports have been filed with the FAERS database.
What Other Side Effects Does ADALIMUMAB Cause?
Drug ineffective (71,926)
Pain (37,514)
Arthralgia (35,592)
Rheumatoid arthritis (29,817)
Fatigue (29,420)
Injection site pain (28,679)
Headache (19,891)
Nausea (19,299)
Rash (18,690)
Pain in extremity (18,319)
What Other Drugs Cause Bladder transitional cell carcinoma?
PIOGLITAZONE (398)
METHOTREXATE (95)
RITUXIMAB (74)
TOCILIZUMAB (68)
INFLIXIMAB (63)
SULFASALAZINE (55)
HYDROXYCHLOROQUINE (50)
PREDNISONE (48)
LENALIDOMIDE (42)
RANITIDINE (41)
Which ADALIMUMAB Alternatives Have Lower Bladder transitional cell carcinoma Risk?
ADALIMUMAB vs ADALIMUMAB-AACF
ADALIMUMAB vs ADALIMUMAB-AATY
ADALIMUMAB vs ADALIMUMAB-ADAZ
ADALIMUMAB vs ADALIMUMAB-ADBM
ADALIMUMAB vs ADALIMUMAB-AFZB